ORGO
NASDAQ · Biotechnology
Organogenesis Holdings Inc
$1.41
-0.01 (-0.70%)
Open$1.41
Previous Close$1.42
Day High$1.42
Day Low$1.38
52W High$7.08
52W Low$1.36
Volume—
Avg Volume697.2K
Market Cap175.00M
P/E Ratio—
EPS$-0.69
SectorBiotechnology
Analyst Ratings
Strong Sell
7 analysts
Price Target
+492.2% upside
Current
$1.41
$1.41
Target
$8.35
$8.35
$5.30
$8.35 avg
$10.56
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 561.48M | 521.05M | 163.70M |
| Net Income | 36.85M | 30.78M | 15.03M |
| Profit Margin | 6.6% | 6.2% | 9.2% |
| EBITDA | 59.68M | 52.61M | 20.76M |
| Free Cash Flow | — | — | 17.26M |
| Rev Growth | +7.8% | +7.8% | +17.3% |
| Debt/Equity | 0.05 | 0.05 | 0.16 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $264.48 | +0.20% | 74.0 | 466.74B |
| AMGN | Amgen Inc | $393.16 | +1.95% | 23.7 | 207.25B |
| GILD | Gilead Sciences Inc | $150.56 | +0.30% | — | 187.10B |
| VRTX | Vertex Pharmaceuticals Inc | $510.72 | +0.47% | 29.7 | 130.64B |
| REGN | Regeneron Pharmaceuticals | $798.17 | +1.70% | 18.6 | 80.58B |
| ALNY | Alnylam Pharmaceuticals Inc | $244.32 | +1.99% | 40.0 | 32.33B |